{
  "meta": {
    "title": "Immunosuppressants_Drugs",
    "url": "https://brainandscalpel.vercel.app/immunosuppressants-drugs-5f509733.html",
    "scrapedAt": "2025-11-29T18:33:31.268Z"
  },
  "questions": [
    {
      "id": 10909,
      "choices": [
        {
          "id": 43602,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab directly inhibits the proliferation of T-cells</span></span></span></p>"
        },
        {
          "id": 43603,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab promotes the activation of B-cells</span></span></span></p>"
        },
        {
          "id": 43604,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells</span></span></span></p>"
        },
        {
          "id": 43605,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Basiliximab enhances the differentiation of dendritic cells</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements best describes the mechanism of action of basiliximab?</span></span></span></p>",
      "unique_key": "Q6966459",
      "question_audio": null,
      "question_video": null,
      "map_id": 36493,
      "difficulty_level": "beginner",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Basiliximab blocks the binding of interleukin-2 (IL-2) to its receptor on activated T-cells</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Basiliximab</strong> is a<strong> chimeric (human-murine) monoclonal antibody </strong>that targets the<strong> IL-2 receptor alpha chain </strong>(also known as <strong>CD25</strong>) on the <strong>surface of activated T-cells.</strong> By <strong>binding </strong>to<strong> this receptor</strong>,<strong> basiliximab</strong> effectively<strong> prevents interleukin-2 (IL-2)</strong> from <strong>interacting with</strong> its receptor.<strong> IL-2</strong> is a crucial <strong>growth factor for T-cells, </strong>particularly following <strong>antigen exposure</strong>. Without the<strong> ability to bind to its</strong> <strong>receptor, IL-2 cannot signal the T-cell to proliferate and activate</strong>, which is essential in the <strong>immune response</strong>, especially concerning the <strong>rejection of transplanted organs.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Basiliximab directly inhibits the proliferation of T-cells:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect.</strong> because <strong>basiliximab </strong>itself <strong>does not </strong>directly<strong> inhibit cell</strong> <strong>proliferation;</strong> instead, it<strong> prevents IL-2</strong> from <strong>activating T-cells, </strong>which<strong> indirectly inhibits their proliferation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Basiliximab promotes the activation of B-cells:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect. Basiliximab&rsquo;s</strong> action is specific to <strong>T-cells </strong>and <strong>does not</strong> involve <strong>direct effects on B-cell activation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Basiliximab enhances the differentiation of dendritic cells:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong>. Basiliximab&#39;s mechanism of action is <strong>centered on T-cells </strong>and <strong>does not </strong>affect the <strong>differentiation of dendritic cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Basiliximab</strong> serves as an<strong> immunosuppressant </strong>by specifically <strong>blocking the IL-2 receptor on activated T-cells</strong>, thereby <strong>preventing</strong> their <strong>activation and proliferation. </strong>This selective<strong> inhibition</strong> is critical in <strong>preventing organ rejection </strong>following <strong>transplantation,</strong> making <strong>basiliximab</strong> a<strong> valuable therapeutic</strong> tool in<strong> transplant medicine.</strong></span></span></span></p>",
      "correct_choice_id": 43604,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10905,
      "choices": [
        {
          "id": 43586,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tofacitinib inhibits Janus kinase (JAK) enzymes</span></span></span></p>"
        },
        {
          "id": 43587,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor</span></span></span></p>"
        },
        {
          "id": 43588,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tocilizumab is approved for the treatment of rheumatoid arthritis</span></span></span></p>"
        },
        {
          "id": 43589,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tofacitinib is administered by intravenous route</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is false about tofacitinib and tocilizumab?</span></span></span></p>",
      "unique_key": "Q7189761",
      "question_audio": null,
      "question_video": null,
      "map_id": 36490,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Tofacitinib is administered by intravenous route</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This statement is <strong>false</strong>. <strong>Tofacitinib</strong> is <strong>not</strong> administered <strong>intravenously</strong>; it is an <strong>orally administered </strong>medication. This <strong>distinguishes it</strong> <strong>from</strong> many <strong>other biologic drugs </strong>used in the treatment of conditions like <strong>rheumatoid arthritis</strong>, which are often <strong>administered via injection or infusion.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Tofacitinib inhibits Janus kinase (JAK) enzymes.</span></strong><span style=\"font-size:12.0pt\"><strong> True.</strong> <strong>Tofacitinib functions </strong>as a <strong>Janus kinase inhibitor,</strong> <strong>targeting</strong> and <strong>inhibiting these enzymes</strong>, which are <strong>crucial in the signaling pathways</strong> for various<strong> inflammatory processes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tocilizumab is a monoclonal antibody against interleukin-6 (IL-6) receptor - </span></strong><span style=\"font-size:12.0pt\"><strong>True.</strong> <strong>Tocilizumab </strong>is a<strong> monoclonal antibody</strong> that <strong>specifically binds</strong> to and <strong>inhibits the IL-6 receptor,</strong> thereby impacting the <strong>action of interleukin-6, </strong>a <strong>cytokine</strong> involved in <strong>inflammation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tocilizumab is approved for the treatment of rheumatoid arthritis - </span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>True. Tocilizumab </strong>has been <strong>approved for</strong> the treatment of<strong> rheumatoid arthritis</strong>, particularly for patients who <strong>have not </strong>responded <strong>adequately to other treatments.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/07/screenshot-2024-05-07-122248.png\" style=\"height:434px; width:1000px\" /></span></u></strong></span></span></p>",
      "correct_choice_id": 43589,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10908,
      "choices": [
        {
          "id": 43598,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Azathioprine is used as immunosuppressant drug</span></span></span></p>"
        },
        {
          "id": 43599,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase)</span></span></span></p>"
        },
        {
          "id": 43600,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fludarabine is the drug of choice for CLL.</span></span></span></p>"
        },
        {
          "id": 43601,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cladribine is degraded by adenosine deaminase</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 52-year-old male with a history of chronic lymphocytic leukemia (CLL) is seen in the oncology clinic for a routine follow-up. His treatment regimen includes a purine analog, and his latest lab tests show a good response to the therapy.&nbsp;Which of the following statements is NOT true about purine analogs?</span></span></span></p>",
      "unique_key": "Q1775454",
      "question_audio": null,
      "question_video": null,
      "map_id": 36492,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Cladribine is degraded by adenosine deaminase</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This statement is <strong>false</strong>. <strong>Cladribine </strong>is actually<strong> resistant to degradation by adenosine deaminase,</strong> which makes it an <strong>effective agent</strong> in treating cancers like<strong> hairy cell leukemia.</strong> Its<strong> resistance</strong> allows it to <strong>remain active longer</strong> and<strong> exert sustained effects </strong>against <strong>cancer</strong> <strong>cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Purine analogs</strong> are a critical class of drugs used in the <strong>treatment of</strong> <strong>various leukemias,</strong> including<strong> CLL.</strong> They function by <strong>mimicking</strong> <strong>natural purines,</strong> integrating into <strong>DNA strands</strong>, and<strong> disrupting DNA synthesis</strong>, which is crucial for the <strong>proliferation of cancer cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Azathioprine is used as an immunosuppressant drug:</span></strong><span style=\"font-size:12.0pt\"> <strong>True.</strong> Azathioprine <strong>inhibits DNA synthesis</strong>, effectively <strong>suppressing</strong> the<strong> immune response</strong>, which i<strong>s beneficial</strong> in conditions like <strong>autoimmune diseases </strong>and in <strong>preventing organ transplant rejection.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Some of these drugs are activated by hypoxanthine guanine phosphoribosyl transferase (HGPRTase):</span></strong><span style=\"font-size:12.0pt\"> <strong>True.</strong> Drugs like <strong>mercaptopurine and thioguanine</strong> need activation by<strong> HGPRTase</strong> to exert their <strong>cytotoxic effects,</strong> making them <strong>effective</strong> in certain <strong>types of leukemia</strong> where this<strong> enzyme is active.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fludarabine is the drug of choice for CLL:</span></strong><span style=\"font-size:12.0pt\"><strong> True.</strong> <strong>Fludarabine</strong> is commonly <strong>used and highly effective</strong> in the treatment of <strong>CLL</strong> due to its<strong> potent ability </strong>to <strong>interfere with DNA replication </strong>in the<strong> rapidly dividing leukemic cells.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cladribine&#39;s resistance</strong> to <strong>adenosine deaminase </strong>makes it a particularly <strong>potent choice in certain leukemias</strong>, contrary to the<strong> incorrect</strong> claim of <strong>its degradation by this enzyme.</strong></span></span></span></p>",
      "correct_choice_id": 43601,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 10921,
      "choices": [
        {
          "id": 43650,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It is a macrolide lactone</span></p>"
        },
        {
          "id": 43651,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It inhibits the gene transcription of interleukin 2</span></p>"
        },
        {
          "id": 43652,
          "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">It acts by binding to immunophilins</span></p>"
        },
        {
          "id": 43653,
          "text": "<p><span style=\"font-size:12.0pt;\">Hirsutism is more common than cyclosporine</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">All the following statements are true about tacrolimus except:</span></p>",
      "unique_key": "Q4902967",
      "question_audio": null,
      "question_video": null,
      "map_id": 36491,
      "difficulty_level": "intermediate",
      "subjects_id": [
        4
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Ans. D) Hirsutism is more common than cyclosporine</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The statement is<strong> incorrect. Hirsutism, or excessive hair growth</strong>, is a <strong>known side effect</strong> associated <strong>more frequently with cyclosporine,</strong> <strong>another immunosuppressant </strong>used in <strong>similar clinical settings</strong> as <strong>tacrolimus</strong>. <strong>Tacrolimus</strong> may cause<strong> hirsutism </strong>as well, but it is significantly<strong> less common</strong> compared to<strong> cyclosporine.</strong> Therefore, stating that <strong>hirsutism is more common with tacrolimus </strong>than with<strong> cyclosporine is false.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A. It is a macrolide lactone:</strong> <strong>True</strong>. <strong>Tacrolimus is a macrolide lactone</strong>; it is structurally similar to <strong>other macrolides</strong> like <strong>erythromycin and azithromycin</strong> but has a <strong>different function, primarily as an immunosuppressant.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option B. It inhibits the gene transcription of interleukin 2:</strong> <strong>True</strong>.<strong> Tacrolimus</strong> i<strong>nhibits the activation of T-lymphocytes</strong> by<strong> inhibiting</strong> <strong>calcineurin</strong>, which in turn <strong>reduces the transcription of interleukin-2 (IL-2).</strong> IL-2 is critical for the<strong> growth and activation of T-cells</strong>, so its <strong>suppression</strong> is key to<strong> tacrolimus's ability </strong>to <strong>prevent organ rejection </strong>in<strong> transplant patients.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option C. It acts by binding to immunophilins:</strong> <strong>True</strong>. <strong>Tacrolimus</strong> binds specifically to the <strong>immunophilin</strong> known as <strong>FK506 binding</strong> <strong>protein (FKBP)</strong>, forming a <strong>complex</strong> that <strong>inhibits calcineurin,</strong> a necessary enzyme in the <strong>T-cell activation pathway.</strong> This action is crucial for <strong>its immunosuppressive effects.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">While <strong>tacrolimus</strong> shares some <strong>mechanisms of action</strong> with <strong>other immunosuppressants</strong> like <strong>cyclosporine,</strong> notably its <strong>suppression of T-cell activation</strong> via <strong>calcineurin inhibition</strong>, it <strong>does not </strong>cause <strong>hirsutism</strong> as commonly as cyclosporine does. This distinction is important in <strong>clinical practice </strong>when choosing an <strong>immunosuppressant</strong>, especially considering the <strong>side effect</strong> profiles that can affect <strong>patient compliance and quality of life.</strong></span></p>",
      "correct_choice_id": 43653,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}